Biomarkers of Disease and Treatment in Murine and Cynomolgus Models of Chronic Asthma by Louten, Jennifer et al.
Biomarker Insights 2012:7 87–104
doi: 10.4137/BMI.S9776
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com.
Biomarker Insights
O r I g I n A L  r e S e A r c h
Biomarker Insights 2012:7 87
Biomarkers of Disease and Treatment in Murine  
and cynomolgus Models of chronic Asthma
Jennifer Louten1,3, Jeanine D. Mattson1, Maria-christina Malinao1, Ying Li1, claire emson1,  
Felix Vega1, robert L. Wardle2, Michael r. Van Scott2, robert B. Fick1, Terrill K. Mcclanahan1,  
rene de Waal Malefyt1 and Maribel Beaumont1
1Merck research Laboratories (formerly Schering-Plough Biopharma) Palo Alto, california USA. 2east carolina University, 
greenville, north carolina USA. 3Department of Biology and chemistry, Southern Polytechnic State University, Marietta, 
gA USA. corresponding author email: maribel.beaumont@merck.com
Abstract
Background: Biomarkers facilitate early detection of disease and measurement of therapeutic efficacy, both at clinical and experimen-
tal levels. Recent advances in analytics and disease models allow comprehensive screening for biomarkers in complex diseases, such as 
asthma, that was previously not feasible. 
Objective: Using murine and nonhuman primate (NHP) models of asthma, identify biomarkers associated with early and chronic stages 
of asthma and responses to steroid treatment. 
Methods: The total protein content from thymic stromal lymphopoietin transgenic (TSLP Tg) mouse BAL fluid was ascertained by 
shotgun proteomics analysis. A subset of these potential markers was further analyzed in BAL fluid, BAL cell mRNA, and lung tissue 
mRNA during the stages of asthma and following corticosteroid treatment. Validation was conducted in murine and NHP models of 
allergic asthma. 
Results: Over 40 proteins were increased in the BAL fluid of TSLP Tg mice that were also detected by qRT-PCR in lung tissue and 
BAL cells, as well as in OVA-sensitive mice and house dust mite-sensitive NHP. Previously undescribed as asthma biomarkers, KLK1, 
Reg3γ, ITLN2, and LTF were modulated in asthmatic mice, and Clca3, Chi3l4 (YM2), and Ear11 were the first lung  biomarkers to 
increase during disease and the last biomarkers to decline in response to therapy. In contrast, GP-39, LCN2, sICAM-1, YM1, Epx, 
Mmp12, and Klk1 were good indicators of early therapeutic intervention. In NHP, AMCase, sICAM-1, CLCA1, and GP-39 were 
reduced upon treatment with corticosteroids. 
Conclusions and clinical relevance: These results significantly advance our understanding of the biomarkers present in various tissue 
compartments in animal models of asthma, including those induced early during asthma and modulated with therapeutic intervention, 
and show that BAL cells (or their surrogate, induced sputum cells) are a viable choice for biomarker examination.
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Introduction
Asthma is a chronic disease of the airways that 
leads to eosinophilia, lung remodeling, excess 
mucus secretion, and bronchoconstriction to non-
specific  spasmogens.1 A hallmark of the disease is 
the activation of Th2 cells that produce IL-4, IL-5, 
and IL-13, which in turn contribute to the devel-
opment of the characteristic symptoms of asthma. 
Asthma affects over 130 million people world-
wide, and as such, many pharmaceutical companies 
are attempting to develop efficacious therapeutics 
for the disease.
A “biomarker” is an objectively measured indica-
tor that reflects the presence, progression, or success-
ful treatment of a particular condition. Biomarkers 
have long been used in drug development, and the 
discovery and validation of new efficacy biomark-
ers is expected to reduce the time and cost associated 
with drug development and therefore increase the 
success rate of translating experimental drugs into 
clinical therapeutics.2 They are valuable both in non-
clinical and clinical studies for improving predictive 
disease models, monitoring potential drug candidate 
efficacy, and detecting early pathology and changes 
in disease status.
The collection of proteins expressed during a dis-
ease (ie, the disease proteome) is particularly useful 
for the discovery of disease and treatment biomark-
ers. Although plasma analysis is common due to 
the ease of accessibility, biological fluids or tissues 
from the local site of pathology, known as “proxi-
mal  fluids,” often represent a more accurate state 
of the condition. In this study, we examined proxi-
mal fluids and tissues from murine and nonhuman 
primate (NHP) models of chronic asthma to iden-
tify and qualify predictive markers of asthma pro-
gression and treatment efficacy. Thymic stromal 
lymphopoietin Transgenic (TSLP Tg) mice express 
TSLP under the lung-specific surfactant protein 
C promoter and thereby develop the hallmarks of 
human asthma over the course of 12 weeks.3 BAL 
fluid, lung tissue mRNA, or BAL cell mRNA from 
TSLP Tg mice was used to identify biomarkers of 
chronic and developing asthma.  Dexamethasone was 
administered to TSLP Tg mice with chronic disease 
to characterize which biomarkers are modulated 
with treatment. Finally, asthma disease and treat-
ment biomarkers were validated in a house dust mite 
allergen (HDMA)-sensitive cynomolgus macaque 
model of chronic allergic asthma before and after 
 corticosteroid treatment. Taken together, the results 
comprise a comprehensive examination of biomark-
ers expressed in proximal fluids and tissues across 
multiple established animal models of asthma and at 
different stages of progression and treatment.
Methods
Mice and in vivo protocols
SPC-TSLP Tg mice, on the BALB/c background, 
were obtained from the laboratory of Steven Ziegler.3 
 Non-transgenic littermates served as control mice; 
male or female cohorts were used in individual  studies 
and were always age- and sex-matched. BALB/c 
mice were purchased from the Jackson Laboratory 
for ovalbumin (OVA)-induced asthma experiments, 
as described below. In dexamethasone-treatment 
 experiments, 12 week-old TSLP Tg mice were injected 
i.p. daily for 1 week with 2 mg/kg dexamethasone 
21-phosphate disodium salt (Sigma) in sterile PBS, 
or with sterile PBS alone as a control. Colonies were 
maintained in a specific pathogenic-free environment. 
Handling of mice and experimental procedures were 
conducted in accordance with the guidelines of the 
AAALAC-accredited Schering-Plough Biopharma 
Animal Care and Use Committee. 
Standard model of OVA-induced  
asthma in mice
For the standard model of OVA-induced asthma, mice 
were sensitized i.p. with 50 ug of ovalbumin from 
chicken egg white (Sigma-Aldrich) complexed to 
2 mg of Imject Alum (Pierce) in 0.15 M saline (Sigma-
Aldrich) on day 0 and day 14, and primed 2 times on Day 
27 and 28 with saline or nebulized OVA (10 mg/mL) for 
45 min per session. Mice were given a final challenge 
of saline or OVA (25 mg/mL) on day 29, and tissues 
were harvested 1 day following OVA challenge.
Harvest of murine BAL fluid,  
BAL cells, and lung tissue
BAL fluid was isolated by washing the lung (through 
the trachea) with 1 mL of PBS. Lavage fluid was 
kept on ice and centrifuged at 400 g for 5 min. The 
supernatant was frozen for cytokine analysis, and the 
cell pellet was resuspended in 1 mL of PBS for total 
viable cell count by Vicell (Perkin-Elmer) and cell 
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differentials by cytospin. Slides were air-dried, fixed 
with 95% ethanol, and stained with  Wright- Giemsa 
 (Sigma-Aldrich). A minimum of 200 cells were 
counted under the microscope per slide for cell 
 differentials. The postcaval lung lobe and pooled 
BAL cells were collected and snap-frozen in liquid 
nitrogen for qRT-PCR analysis as described previ-
ously for tissue4 and below for BAL cells. The single 
left lung lobe was excised for histology and clinical 
scoring as described below.
Pulmonary function (Plethysmography) 
of dexamethasone-treated mice
Murine pulmonary responses to the non-specific 
bronchoconstrictor methacholine chloride were mea-
sured using Whole Body Plethysmography (WBP) 
(Buxco Electronics). Unrestrained mice were placed 
in individual chambers and exposed to nebulized 
methacholine (5 mg/mL) for 1 minute, and responses 
were recorded for the following 3 minutes. Penh was 
calculated to quantify lung function.
Murine lung histology and clinical scoring
Murine lungs were perfused with 10 mL of PBS 
via the right ventricle of the heart. The single left 
lung lobe was excised, fixed in 10% neutral buff-
ered  formalin, paraffin-embedded, sectioned, and 
stained with hematoxylin and eosin. Lung tissue was 
scored for hypertrophy of the airway epithelium and 
peribronchiolar/perivascular cellular inflammation on 
a scale of 0–5 by a board-certified pathologist.
mrnA isolation from BAL cells  
and qrT-Pcr
Total RNA was isolated from BAL cells using the 
RNeasy method (Qiagen) and reverse- transcribed 
using WT-Ovation™ Pico System (NuGen 
 Technologies). Primers were designed using Primer 
Express software (Applied Biosystems) or obtained 
commercially from Applied Biosystems (ABI). 
 qRT-PCR was performed on 10 ng of cDNA from 
each sample as described previously.4
LC-MS/MS analysis of BAL fluid proteins
An equal volume of murine or cynomolgus BAL fluid 
was separated on a preparative 4%–12% NuPage gel 
and stained with GelCode Coomassie Blue (Pierce). 
Each lane was sliced into an equal number of 
bands and digested with sequencing-grade modified 
trypsin using a Progest (Genomic Solutions). Mass 
 spectrometry was performed as described below. 
LC-MS/MS raw files were searched using the Mascot 
v2.1.6 software package (Matrix Sciences) against 
the mouse subset of the National Center for Biotech-
nology Information (NCBI) non-redundant protein 
database (updated as of August 2006) for murine 
BAL fluid and against the entire database (including 
all species, updated as of December 2007) for mon-
key BAL fluid.  Categorization of proteins by function 
was performed using Ingenuity Pathway Analysis 
(Ingenuity Systems). LC-MS/MS analyses were per-
formed on BAL fluid from 5, 7, 9, and 12 week old 
TSLP Tg mice with overlapping results; results pre-
sented are from 9-week old mice.
Mass spectrometry
Mass spectrometry was performed using a LCQ Deca 
Ion Trap (ThermoElectron), a 48-well Paradigm AS1 
autosampler (Michrom Bioresources), and a Paradigm 
MS4 HPLC system (Michrom Bioresources). The col-
umn was packed with Vydac C18 resin (5 micron beads, 
300Å pores), 10 cm long with a 15 micron tip (New 
Objectives). The chromatographic separation was per-
formed using a linear gradient elution. Search param-
eters included no restriction on molecular weight or pI, 
fixed modification of cysteine residues (carbamidom-
ethylation), variable modification of methionine resi-
dues (oxidation), a peptide mass tolerance of +/- 1.5 
Daltons, a fragment mass tolerance of +/- 0.8 Daltons, 
and one missed tryptic cleavage. Protein identification 
was based on at least two matching peptides. Protein 
hits with only one matching peptide were reviewed 
manually and included as positive identifications when 
a stretch of at least 4 b or y ions was present.
Western blot analysis of BAL fluid 
samples
Western blot analysis was performed on BAL fluid 
samples. 200 uL of each BAL fluid sample was ace-
tone precipitated in 4 volumes of cold acetone over-
night and resuspended in 1X NuPage LDS sample 
loading buffer. An equal amount was separated on a 
4%–12% NuPage gels, and gels were electroblotted 
onto PVDF membranes overnight at 10V in NuPage 
transfer buffer. Membranes were blocked in 5% fat-
free milk in TBS/T (10 mM Tris-HCl pH 7.5, 100 mM 
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NaCl, 0.1% Tween 20) for 1 hour and incubated with 
specific antibodies according to the manufacturer’s 
instructions in 1% milk in TBS/T for another 2 hours. 
Blots were incubated with HRP-labeled secondary 
antibodies (chicken anti-goat IgG, R&D Systems, 
Minneapolis, MN or donkey anti-rabbit Ig-G, GE 
Healthcare, Piscataway, NJ) in 1% milk in TBS/T 
for another hour and detection was performed with 
ECL+ (GE Healthcare). Primary antibodies used 
included anti-mouse LCN2, anti-mouse sICAM-1, 
anti-human sICAM-1 (for monkey studies), anti-
mouse GP-39, anti-mouse YM1, and anti-mouse 
pIgR (all from R&D Systems); and anti-mouse UG, 
anti-mouse AMCase, anti-human AMCase (for 
 monkey studies), anti-mouse CLCA3, and anti-
 human CLCA1 (for monkey  studies) (all from Santa 
Cruz  Biotechnology). Polyclonal anti-mouse Reg3γ 
was generated at  Schering-Plough Biopharma. After 
autoradiography visualization, membranes were dried 
and scanned on a Typhoon 9400 (GE Healthcare) for 
ECL+ (457 nm excitation and 520BP40 emission). 
Image analysis was conducted using ImageQuant 
v5.2 (GE  Healthcare) and band intensity reported as 
sum of pixel values above background.
eLISAs
Mouse LCN2, GP-39, sICAM-1, and YM1 proteins 
were quantified using Quantikine or DuoSet ELISA 
kits (R&D Systems) using a Vmax  spectrophotometer 
with SoftMax Pro software (Molecular Devices); 
mouse IL-4, IL-5, and IL-13 were measured using a 
Luminex 100 machine with Lincoplex multiplex kits 
(Millipore) and analyzed with MasterPlex  software 
(Miraibio). Monkey YKL-40 was quantified via 
ELISA (Quidel), analyzed as above.
house dust mite allergen (hDMA)-
Induced asthma in nonhuman primates
Juvenile macaques (Cynomolgus fascicularis, 30 to 
42 months of age) were purchased from  Alphagenesis. 
Studies were performed as described.5 Briefly, 
 animals were sensitized to HDMA over a 7.5 month 
period by intraperitoneal injection of 312 AU 
 Dermatophagoides pteronyssinus extract (Greer Lab-
oratories) absorbed to Imject Alum (Pierce) admin-
istered every two weeks until HDMA-specific IgE 
titers approached levels in control allergic serum, and 
then at 4-week intervals until aeroallergen challenge. 
At this time, animals were challenged with nebulized 
HDMA (1 to 2500 AU/mL for 4 minutes) at a con-
centration that induced an early asthmatic response, 
defined as a 100% increase in lung resistance, 40% 
decrease in dynamic compliance, or decline in arterial 
oxygen saturation to #70%. Airway inflammation 
and reactions to nebulized histamine and methacho-
line 24 hours after allergen challenge were measured 
periodically to confirm chronic asthmatic responses. 
Wardle-Fick methods were used to obtain BAL fluid, 
described in further detail below. BAL cells were 
then separated from the fluid phase. Mass spectrom-
etry compared BAL fluid from sensitized animals 
before and after HDMA challenge. In corticosteroid 
treatments experiments, animals were challenged 
with HDMA and BAL fluid was collected 24 hours 
later (“Pre”  steroid). Animals then received weekly 
doses of methylprednisolone acetate (4.5 mg/kg 
intramuscularly) for two weeks, followed by a single 
dose of methylprednisolone succinate (10 mg/kg i.v.) 
one week later at the time of allergen challenge. 
BAL fluid was collected 24 hours following another 
HDMA challenge (“Post” steroid). Animal husbandry 
was conducted under USDA guidelines. All protocols 
were approved by the Institutional Animal Care and 
Use Committee of East Carolina University.
Wardle-Fick methods to obtain BAL fluid 
from cynomolgus monkeys
Each animal received a premedication and 
 anesthesia (vide supra), and Cetacaine spray 
 (Cetylite  Industries, Inc., Pennsauken, NJ) was 
administered locally to the hypopharynx surround-
ing the endotracheal tube. A 2.5 mm or 2.7 mm 
fiberoptic bronchoscope (Five Star Medical or Pen-
tax FB-8V, respectively) was inserted via the endo-
tracheal tube with the assistance of lubrication. The 
bronchoscope was wedged in the posterior division 
of the right upper lobe segment, and 5–10 mL ali-
quots of sterile 0.9% saline, totaling 40 mL, were 
sequentially administered and withdrawn with min-
imal dwell time through the suction channel (gentle 
aspiration, optimally 140–150 mm Hg).
Statistical analyses
The unpaired or paired two-tailed t test was performed 
using GraphPad Prism version 4.02  (GraphPad 
 Software) to determine average ±  standard error 
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of the mean. P , 0.05 was considered statistically 
 significant. *P , 0.05; **P , 0.01; ***P , 0.001.
Results
Identification and validation of protein 
biomarkers in TSLP Tg mice
Biomarkers are valuable in the diagnosis of disease, 
as well as in determining the efficacy of a therapeu-
tic against the disease, thereby increasing the success 
rate of translating experimental drugs into clinical 
therapeutics. To determine which biomarkers are 
modulated in the lung during asthmatic responses, 
TSLP Transgenic (Tg) mice were used as a murine 
model of asthma. These mice express thymic stromal 
lymphopoietin (TSLP) under the lung-specific sur-
factant protein C promoter and begin to develop 
the pathophysiological characteristics of asthma 
at 5 weeks of age. By 9 weeks of age, all the hall-
marks of chronic human asthma, including pulmonary 
 eosinophilia, production of Th2 cytokines, airway 
fibrosis, and hyperplasia of airway epithelium, are 
present (See Figure S1 in the Supplemental Informa-
tion).3 Bronchoalveolar lavage (BAL) was performed 
on the lungs of 9-week old control or TSLP Tg mice, 
the cellular fraction of the BAL was removed, and the 
BAL fluid phase was analyzed by mass spectrometry. 
Approximately 150 proteins were identified, of which 
forty-four were found to be upregulated in the BAL 
fluid, compared to non-Tg wild-type littermate con-
trols (see Table S1 in the Supplemental Information). 
Identified proteins could generally be divided up into 
functional groups (Fig. 1). The majority of classified 
proteins identified in the BAL fluid were considered 
enzymes (30%), whereas a smaller proportion of pro-
teins were classified as transporters (10%), peptidases 
(6%), cytokines (2%), or kinases (2%). Proteins with 
uncharacterized or unclassified functions that did 
not fall into a specific functional group were termed 
“other.”
As mass spectrometry is semi-quantitative, a subset 
of 18 proteins was chosen for further analysis via west-
ern blot, ELISA, and quantitative reverse transcriptase-
PCR (qRT-PCR). Selected proteins were chosen based 
upon availability of reagents and their previous asso-
ciation or lack of association with pulmonary diseases 
(see Discussion for further information). Proteins were 
verified using western blot or ELISA, if reagents were 
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Figure 1. Functional groups of proteins identified in the BAL fluid of TSLP 
Tg mice and WT littermates by mass spectrometry. 
notes: Mass spectrometry was used to identify proteins present in the 
BAL fluid of 9-week old control and asthmatic TSLP Tg mice. Using Inge-
nuity  Pathway  Analysis, proteins were categorized by known function into 
enzymes (30%), transporters (10%), peptidases (6%), transcription regu-
lators (2%), cytokines (2%), kinases (2%), phosphatases (1%), growth 
factors (1%), transmembrane receptors (1%), or ion channels (1%). 
Proteins that did not fall into a specific functional group were termed 
“other” (44%) and consisted of a variety of proteins with uncharacterized 
or unclassified functions. See Table S1 in the Supplemental Information 
for the list of identified proteins.
available. Acidic mammalian chitinase (AMCase; 
gene name Chia), YM1 (YM1; Chi3l3), chloride 
channel regulator 3 (CLCA3; Clca3), the polymeric 
immunoglobulin receptor (pIgR; Pigr), regenerating 
islet-derived 3 gamma (Reg3γ; Reg3g); lipocalin 2 
(LCN2; Lcn2), and intercellular adhesion molecule 1 
(ICAM-1; Icam1) were increased in western blots of 
BAL fluid; some proteins, such as AMCase or CLCA3, 
appeared as doublet bands that were further intensified 
in TSLP Tg mice (Fig. 2A). LCN2, cartilage glycopro-
tein 39 (GP-39; Chi3l1), and sICAM-1 were all highly 
upregulated as measured by ELISA (Fig. 2C).
qrT-Pcr validation of biomarkers  
in murine lung tissue
The expression of 18 putative biomarkers was exam-
ined in the lung tissue of age- and sex-matched control 
versus TSLP Tg mice using qRT-PCR. Interestingly, 
qRT-PCR analysis of TSLP Tg mouse lung tissue for 
these 18 genes showed a large range of relative expres-
sion and fold change that could generally be divided 
into “High” (.6-fold increase) and “Intermediate” 
(1.8- to 6-fold change) expression groups (Table 1). 
Showing the highest upregulation at the mRNA level 
(fold-change . 100) were YM2 (YM2; Chi3l4), 
eosinophil cationic protein (ECP; Ear11), resistin-
like beta (RETNLβ; Retnlb), and Clca3; also falling 
into the “High” category were eosinophil major basic 
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results were similar regardless of the sex of the con-
trol and TSLP Tg mice. Taken together, these results 
show that the 18 selected proteins all function as bio-
markers of murine chronic asthma. They also indicate 
that qRT-PCR analysis of lung tissue mRNA is effec-
tive in assessing certain biomarkers such as Chi3l4, 
Ear11, Retnlb, and Clca3, but that protein assays may 
be more valuable in ascertaining differences in pro-
teins such as GP-39, LCN2, or ICAM-1 that exhibit 
more discernable separations at the protein rather 
than mRNA level.
qrT-Pcr validation of biomarkers  
in BAL cells
Lung tissue is difficult to procure from patients for 
biomarker analyses. However, induced sputum is eas-
ily obtained from individuals due to its relative non-
invasiveness. It is also clinically relevant, as an ample 
number of cells can be acquired in this manner, so 
investigation of sputum cells may prove fruitful for 
effective biomarker analysis. In the mouse, BAL cells 
are considered analogous to human sputum cells, so 
we next analyzed the expression of biomarkers in 
BAL cells from TSLP Tg mice. In addition to the 18 
biomarkers examined in murine lung tissue, we also 
examined 4 putative biomarkers derived from pro-
teins found by mass spectrometry of TSLP Tg mouse 
BAL fluid but not highly upregulated in lung tissue 
by qRT-PCR: Scgb1a1 (Secretoglobin family 1A 
member 1, ie, uteroglobin (UG) or Clara Cell-specific 
10 kD protein (CC-10)), Egfr (Epidermal growth fac-
tor receptor, EGFR), Itln2 (Intelectin-2, ITLN2), and 
Ctsh (Cathepsin H, CTSH). As shown in Table 2, qRT-
PCR expression analysis of the 22 biomarkers gave a 
much different expression profile in BAL cells than 
in lung tissue from TSLP Tg mice. Eosinophil acti-
vation genes Prg2 (EMBP), Epx, and Ear11 (ECP) 
were all highly upregulated in BAL cells, not surpris-
ing as eosinophils constitute over 80% of the BAL 
cells of TSLP Tg mice. The 4 biomarkers with the 
highest upregulation in lung tissue—Chi13l4 (YM2), 
Clca3, Ear11 (ECP), and Retnlb—were also over 
100-fold upregulated in BAL cell mRNA. Mmp12, 
Fcgbp, and Reg3g also remained in the “High” fold-
change category. Klk1, present in the “ Intermediate” 
lung biomarker group (Table 1), was highly expressed 
in BAL cells (Table 2). Conversely, Chi3l3 (YM1), 
which was in the “High” lung biomarker category, 
Figure 2. Verification of putative asthma biomarkers in TSLP Tg mice. 
BAL fluid and lung tissue were collected from control WT and asthmatic 
TSLP Tg mice for further biomarker evaluation. Western blot analysis was 
performed on the BAL fluid of WT or TSLP Tg mice for assessment of 
AMcase, YM1, cLcA3, pIgr, reg3γ, Lcn2, and IcAM-1 (A). Band inten-
sity was determined using ImageQuant v5.2 and reported as the sum of 
the pixel values above background (B). eLISAs were used to quantify the 
amount of GP-39, LCN2, and ICAM-1 in BAL fluid (c).  
notes: results are representative of 3–5 independent experiments. 
***P , 0.001.
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protein (EMBP; Prg2), eosinophil peroxidase (EPX; 
Epx), matrix metallopeptidase 12 (MMP12; Mmp12), 
Chia, Chi3l3, the Fc fragment of IgG binding  protein 
(FCGBP; Fcgbp), and regenerating islet-derived 
3 gamma (Reg3γ; Reg3g), whereas Ltf, Pglyrp1, 
Pigr, kallikrein 1 (KLK1; Klk1), Lcn2, and Chi3l1 
displayed “Intermediate” upregulation. It was sur-
prising that Chi3l1 (GP-39) and Lcn2 (LCN2) were 
only 1.85- and 2.22-fold upregulated at the mRNA 
level, as average protein concentrations of GP-39 and 
LCN2 were 11- and 30-fold increased, respectively, 
in TSLP Tg mouse BAL fluid (Fig. 2C). Interestingly, 
although sICAM-1 was highly upregulated at the pro-
tein level via ELISA (Fig. 2C), Icam1 was not mod-
ulated at the mRNA level (data not shown). These 
Asthma disease and treatment biomarkers
Biomarker Insights 2012:7 93
Table 1. qrT-Pcr analysis of selected biomarker genes in 9-week old WT or TSLP Tg mouse lung tissue.
Gene name WT* TsLp Tg* Fold change
high
 Chi3l4 (YM2) 2.39 ± 1.13 1453.11 ± 511.55 608.31
 Ear11 12.19 ± 3.31 3860.82 ± 1173.10 316.71
 Retnlb 0.32 ± 0.14 68.08 ± 34.40 212.57
 Clca3 16.04 ± 8.13 1172.93 ± 335.42 152.85
 Prg2 (EMBP) 19.09 ± 5.69 734.1 ± 181 38.45
 Epx 6.25 ± 3.59 233.2 ± 64.89 37.31
 Mmp12 193.27 ± 14.53 5182.02 ± 1774.17 26.81
 Chia (AMCase) 395.56 ± 23.63 7358.75 ± 1636.71 18.6
 Chi3l3 (YM1) 478.25 ± 39.94 8639.59 ± 437.79 18.06
 Fcgbp 45.13 ± 0.95 644.46 ± 67.23 14.28
 Reg3g 55.92 ± 16.52 743.43 ± 335.41 13.29
Intermediate
 Ltf 229.35 ± 62.47 1309.18 ± 297.88 5.71
 Pglyrp1 58.59 ± 2.65 333.6 ± 28.62 5.66
 Pigr 137.32 ± 21.13 445.02 ± 42.49 3.24
 Klk1 32.80 ± 5.10 85.77 ± 12.95 2.61
 Lcn2 1439.38 ± 161.21 3195.21 ± 203.18 2.22
 Chi3l1 (GP-39) 2862.49 ± 195.24 5300.17 ± 442.57 1.85
notes: *relative expression units, normalized to ubiquitin, and the SeM. expression units are representative of 3–6 mice per group. results presented 
are representative of 5 independent experiments.
was only intermediately expressed in BAL cell 
mRNA. Scgb1a1 (UG) exhibited high expression 
levels in WT mice, which was further increased 8.55-
fold in TSLP Tg mice. The majority of the BAL cell 
biomarkers exhibited an intermediate level of expres-
sion. Although Chia (AMCase) was in the “High” 
lung expression group, the gene was not expressed in 
BAL cell mRNA.
As BAL cells are a representation of the cellular 
constituents of the asthmatic lung, we reasoned that 
further examination of the chemokine and chemokine 
receptor genes present in the BAL cells of TSLP Tg 
mice would help us identify a “cellular signature” that 
could prove valuable in characterizing the type of cel-
lular inflammation present in the lung and thus the best 
course of treatment. Towards this goal, we examined 
chemokine and chemokine receptor genes that are 
known to participate in asthmatic responses. qRT-PCR 
expression analysis of BAL cell mRNA from WT and 
TSLP Tg mice revealed that Ccr3 was over a thou-
sand-fold upregulated in the asthmatic TSLP Tg mice 
(Table 2), depicting the large eosinophil population in 
the BAL. Although not increased as much as Ccr3, 
chemokine receptors Ccr4 and Ccr6 were also over 
10-fold upregulated. Consistent with the expression of 
their receptors, chemokines Ccl5, Ccl8, Ccl11, Ccl22, 
and Ccl24 were also highly upregulated (between 
7- and several hundred-fold). In contrast, Cxcr1 and 
Cxcr2, receptors for neutrophil-attracting chemokines, 
were not increased (data not shown). These results 
demonstrate that the chemokine and chemokine recep-
tor profile of BAL cells accurately represents the cel-
lular composition of an asthmatic lung.
Biomarker expression in OVA sensitized 
and challenged mice
As TSLP Tg mice have not previously been used as a 
model of chronic asthma to identify disease biomark-
ers, we verified our biomarker findings using the more 
established ovalbumin (OVA)- induced asthma model 
(Table 3, and Table S2 in the Supplemental  Information), 
demonstrating that the chosen set of lung tissue asthma 
biomarkers is similarly upregulated in two different 
murine models of asthma.
Lung biomarker induction  
in early asthma
A criticism of using OVA-induced murine models 
of asthma is the difficulty in delineating biomark-
ers of developing versus chronic asthma. However, 
as TSLP Tg mice begin to develop asthma at 5 weeks 
of age and progress to a state of chronic asthma over 
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Table 2. qrT-Pcr analysis of selected biomarker genes 
in BAL cells of 9-week old WT or TSLP Tg mice.
Gene name WT* TsLp Tg* Fold  
change
high
 Prg2 (EMBP) 0.06 693.53 12002.03
 Epx 0.01 158.61 10813.69
 Chi3l4 (YM2) 4.42 5363.04 1212.53
 Clca3 20.39 21345.26 1046.82
 Retnlb 0.14 47.54 336.66
 Klk1 0.20 40.09 203.08
 Ear11 70.06 9318.96 133.00
 Mmp12 212.80 8432.78 39.63
 Scgb1a1 (UG) 465.03 5788.91 12.45
 Fcgbp 259.87 2468.60 9.50
 Reg3g 136.93 1046.53 7.64
Intermediate
 Itln2 83.58 352.78 4.22
 Pglyrp1 1293.16 5300.36 4.10
 Egfr 10.62 39.39 3.71
 Pigr 1560.77 5523.00 3.54
 Chi3l3 (YM1) 27002.91 95553.46 3.54
 Chi3l1 (GP-39) 0.69 1.95 2.81
 Ctsh 1665.02 3950.66 2.37
 Lcn2 1198.03 2425.46 2.02
 Ltf 591.75 1065.15 1.80
chemokine genes
 Ccl5 (RANTES) 193.70 1363.41 7.04
 Ccl8 (MCP-2) 0.34 231.05 689.65
 Ccl11 (Eotaxin-1) 0.06 9.72 164.35
 Ccl22 (MDC) 6.33 63.40 10.02
 Ccl24 (Eotaxin-2) 0.05 28.51 609.57
 Ccr3 (CD193) 0.05 175.28 3748.13
 Ccr4 (CD194) 1.16 13.28 11.47
 Ccr6 (CD196) 6.56 79.27 12.09
notes: *relative expression units, normalized to ubiquitin. qrT-Pcr 
results presented are derived from rnA pooled from 3–6 mice per group. 
results presented are representative of 5 independent experiments.
the subsequent 4 weeks, these mice can be used to 
examine our biomarker set during the development 
of asthma. At 5 weeks of age, TSLP Tg mice exhibit 
mucus production and minor cellular inflammation 
around airways and vasculature but lack the mas-
sive  inflammation, tissue remodeling, airway hyper-
trophy, and eosinophilia present at 9 weeks. mRNA 
was isolated from the lung tissue of 5 week-old 
mice, and qRT-PCR was performed for the set of 18 
lung biomarkers (see Table S3 in the Supplemental 
Information). BAL cell mRNA expression was not 
analyzed due to the scarcity of BAL cell infiltrates 
at this 5-week time point. Whereas the lung tissue 
of 9 week old mice had 11 biomarkers in the “High” 
category, only 5 biomarkers fell into the “High” cat-
egory in 5 week old mice with developing asthma 
(Table 3): Clca3, Chi3l4 (YM2), and Ear11 (ECP) 
were over 100-fold increased, and the relative 
expression of Retnlb was much lower at 5 weeks 
(16-fold increased instead of 212-fold increased), 
whereas the upregulation of Fcgbp was similar in at 
both ages. These results indicate that CLCA3, YM2, 
ECP, RETNLβ, and FCGBP are expressed early in 
asthma pathogenesis and may be effective biomark-
ers of developing asthma.
Biomarkers modulated with 
dexamethasone treatment
Having identified a set of disease biomarkers in the 
BAL fluid, lung tissue mRNA, and BAL cell mRNA 
of asthmatic mice, we next sought to determine which 
biomarkers are reduced with treatment. As corticos-
teroid treatments have been proven highly effective 
as the standard of care for the disease, we adminis-
tered systemic dexamethasone daily for one week 
to 12-week old TSLP Tg mice. Whereas 9-week old 
mice were used for biomarker analysis, 12-week old 
mice were used for dexamethasone treatment stud-
ies because their continued asthma pathogenesis, 
with extensive tissue remodeling and allergic inflam-
mation, is a better analogy to severe chronic human 
asthma before treatment. When challenged with aero-
solized saline, TSLP Tg mice exhibit worse basal 
lung function (Penh) than control mice, as measured 
by whole body plethysmography. They also have 
high Penh values when challenged with a very small 
dose (5 mg/mL) of methacholine chloride (Fig. 3A). 
Dexamethasone treatment of the TSLP Tg mice sig-
nificantly improved both basal and challenged lung 
function. Correspondingly, dexamethasone treat-
ment significantly reduced lung weight (Fig. 3B), 
lung pathology score (Fig. 3C), total number of BAL 
cells (Fig. 3D), and percentage of BAL eosinophils 
(Fig. 3E) in TSLP Tg mice. Although significantly 
decreased, these parameters were not absent with 
treatment, allowing us to discern which biomarkers 
are more quickly modulated with treatment.
Several biomarkers were downregulated in the 
BAL fluid of dexamethasone-treated TSLP Tg mice, 
including CLCA3, YM1, and pIgR (via western 
blot, Fig. 4A), as shown previously,6 and GP-39, 
LCN2, sICAM-1, and YM1 (via ELISA, Fig. 4B). 
 Interestingly, although Chi3l4 (YM2), Ear11, Retnlb, 
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Table 3. comparison of biomarker gene upregulation in 
9-week old TSLP Tg mice, 5-week old TSLP Tg mice (with 
developing asthma), and OVA-challenged mice.
Gene name Average fold change
TsLp Tg  
vs. WT 
(9 weeks)
TsLp Tg  
vs. WT 
(5 weeks)
OVA vs. 
saline
Chi3l4 (YM2) 608.31 383.34 2377.87
Ear11 316.71 101.52 276.77
Retnlb 212.57 16.35 270.7
Clca3 152.85 427.13 526.22
Prg2 (EMBP) 38.45 2.16* 9.05
Epx 37.31 1.09 10.33
Mmp12 26.81 3.04* 37.67
Chia (AMCase) 18.6 1.68* 9.76
Chi3l3 (YM1) 18.06 3.41* 18.03
Fcgbp 14.28 11.09 13.33
Reg3g 13.29 1.88* 2.83*
Ltf 5.71* 2.16* -1.37
Pglyrp1 5.66* 1.6* 2.21*
Pigr 3.24* 2.32* 3.97*
Klk1 2.61* 1.39 4.11*
Lcn2 2.22* 1.16 2.81*
Chi3l1 (GP-39) 1.85* 1.03 2.17*
notes: Bold-faced text indicates a value that falls into the “high” 
expression category (.6-fold upregulated); asterisks indicate a value 
that falls into the “Intermediate” expression category (1.5- to 6-fold 
increased). Average relative expression units and SeM for 9-week TSLP 
Tg, 5-week TSLP Tg, and OVA-treated mice are found in Tables 1, S3, 
and S2, respectively.
Figure 3. reduction of asthma symptoms upon dexamethasone treat-
ment in TSLP Tg mice. TSLP Tg mice were treated daily with 2 mg/kg 
dexamethasone (DeX) i.p. for 2 weeks. Lung function was measured in 
WT (“WT”), TSLP Tg (“Tg”), or DeX-treated TSLP Tg mice (“Tg+DeX”) 
by whole body plethysmography upon saline or 5 mg/mL methacho-
line chloride challenge (A) Lung tissue was harvested and the weight 
of the superior lung lobe was measured (B) h&e stained lung tissue 
was scored for hypertrophy of the airway epithelium and peribronchiolar/ 
perivascular cellular inflammation on a scale of 0–5 by a board-certified 
pathologist (c) The total number of BAL cells was determined using try-
pan blue exclusion criteria on a Vicell counter (D), and the proportion of 
eosinophils in the BAL was enumerated by Wright-giemsa staining of 
cytospun cells (e) A minimum of 200 cells were counted. 
notes: results presented are the combined data points of 3 independent 
experiments totaling 12 mice per group. *P , 0.05; **P , 0.01; 
***P , 0.001.
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and Clca3 showed the highest fold-upregulation of 
any of the biomarkers in lung tissue from TSLP Tg 
mice (Table 1), none of these were modulated with 
dexamethasone treatment at the mRNA level (data 
not shown). In contrast, several of the other bio-
markers in the “High” lung biomarker category were 
reduced with treatment: Prg2 (EMBP), Epx, Mmp12, 
Chia (AMCase), and Chi3l3 (Ym1) were down-
regulated (Fig. 4C), although expression of Fcgbp 
and Reg3g—also in the “High” lung biomarker 
category—was unaffected (data not shown). In the 
“Intermediate” lung biomarker group, Ltf, Pigr, Klk1, 
and Chi3l1 (GP-39) were all reduced with dexame-
thasone (Fig. 4C), whereas expression of Pglyrp1 and 
Lcn2 were not diminished at the mRNA level (data 
not shown), despite that LCN2 protein levels were 
significantly lowered (Fig. 4B).
In BAL cell mRNA from dexamethasone-treated 
mice, the biomarkers with the largest increase (Prg2, 
Epx, Chi3l4, Clca3, Retnlb, and Klk1) were all down-
modulated with treatment (Fig. 4D). Ear11 was not 
reduced, which was surprising as Prg2 and Epx, the 
other two eosinophil activation genes, were reduced 
in both lung tissue and BAL cell mRNA. Scgb1a1 
(UG), Fcgbp, Itln2, Pglyrp1, and Ctsh were also 
reduced in BAL cell mRNA upon treatment (Fig. 4D). 
Together, these results show that corticosteroid treat-
ment quickly reduces the highest upregulated bio-
markers in BAL cells but not lung tissue, indicating 
that BAL cells may be more useful for monitoring 
asthma treatment biomarkers.
As the percentage of eosinophils and total num-
ber of BAL cells were reduced in TSLP Tg mice 
treated with dexamethasone (Fig. 3D and E), we 
next examined chemokine and chemokine recep-
tor genes in BAL cell mRNA, pooled per group. 
Th2 cell chemokine Ccl22 and eosinophil chemok-
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Figure 4. Downregulation of biomarkers in dexamethasone-treated TSLP Tg mice. TSLP Tg mice were treated with dexamethasone for 2 weeks, at which 
time BAL fluid was collected for western blot and band density analysis (A) of cLcA3, YM1, and pIgr or eLISA (B) of gP-39, Lcn2, sIcAM-1, and YM1. 
qrT-Pcr of lung tissue (c) and pooled BAL cells (D) was performed for biomarker genes, and expression of chemokine (e) and chemokine receptor (F) 
genes was also assayed by qrT-Pcr of pooled (per group) BAL cell mrnA. 
notes: Percentages indicated represent the % reduction of the respective biomarker in dexamethasone-treated TSLP Tg mice (“Tg+DeX”), compared 
to control-treated TSLP Tg mice (“Tg”). results are representative of 3 independent experiments. P values cannot be determined for experiments using 
pooled mrnA. *P , 0.05; **P , 0.01; ***P , 0.001.
ines Ccl5, Ccl8, Ccl11, and Ccl24 were all reduced 
with dexamethasone treatment (Fig. 4E). Consistent 
with the reduction in chemokine genes, chemokine 
receptors Ccr3, Ccr4, and Ccr6 were all downregu-
lated with treatment (Fig. 4F). Thus, corticosteroid 
treatment reduces a subset of disease biomarkers in 
BAL fluid, lung tissue, and BAL cells and affects the 
 expression of eosinophil and lymphocyte chemokine 
and chemokine receptor genes present in BAL cell 
mRNA of asthmatic TSLP Tg mice.
Verification of asthma biomarkers  
in a cynomolgus model of asthma
Although several of the biomarkers we verified have 
been individually documented to be involved in 
human asthma, we sought to further validate our set 
of biomarkers in a model of chronic asthma closer to 
human disease. Towards this goal, we used a house 
dust mite allergen (HDMA)-induced asthma model in 
cynomolgus macaques (Macaca fascicularis). As pre-
viously described, HDMA-sensitized animals present 
with a Th2 phenotype characterized by airway eosino-
philia, bronchial hyperresponsiveness, and goblet cell 
metaplasia.5,7 Mass spectrometry was performed on 
BAL fluid from HDMA-sensitized  animals 24 hours 
before or after challenge with HDMA.  Seventy 
 identified proteins were upregulated in the BAL fluid 
of challenged NHP (Table S4), eight of which were 
also identified in the BAL fluid of asthmatic TSLP 
Tg mice: apoH, CLCA1/3, Factor H, Fibronectin 1, 
FCGBP, LCN2, pIgR, and S100A9. Although not 
identical, several upregulated proteins were identi-
fied from similar families in NHP and mouse, such 
as cyclophilin A and cyclophilin B/C or serpin A1 
and serpin B6, respectively. It is important to note 
that several murine proteins are not expressed in 
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higher mammals (eg, lungkine, YM1, or YM2), and 
as less information is known at the protein level for 
M. fascicularis than for mouse or human, it is likely 
that monkey proteins with lesser homology to their 
human counterparts were not positively identified.
Although many reagents do not exist for the anal-
ysis of NHP proteins, antibodies have been made 
against several of the human orthologs of the murine 
biomarker proteins that exhibit cross-reactivity with 
NHP proteins. Present at very high amounts in the 
BAL fluid of HDMA-challenged animals were YKL40 
and PAP (the human ortholog of GP-39 and Reg3γ, 
respectively) (by ELISA) and AMCase, ICAM-1, 
LCN2, UG, pIgR, and CLCA1 (the human ortholog of 
murine CLCA3) (by western blot) (data not shown). 
As these results were consistent with the studies per-
formed in TSLP Tg mice, we next examined which of 
these biomarkers were modulated with corticosteroid 
treatment. Towards this end, BAL fluid was collected 
from HDMA-challenged NHP either before (“Pre”) 
or after (“Post”) 2 weeks of high-dose corticosteroid 
therapy. As expected, corticosteroid-treated animals 
exhibited reduced asthma characteristics, such as 
improved lung function and reduced airway eosino-
phil recruitment (data not shown). Although trending 
downward, the expression of LCN2, UG, pIgR, PAP, 
and CLCA1 was not significantly reduced in BAL 
fluid following corticosteroid treatment (data not 
shown); however, AMCase, sICAM-1, CLCA1 (all 
by western blot) and GP-39 (by ELISA) were signifi-
cantly reduced in corticosteroid-treated challenged 
animals (Fig. 5A and B), similar to results obtained 
in dexamethasone-treated TSLP Tg mice (see Fig. 4A 
and B). Taken together, these results indicate that 
the disease and treatment biomarkers characterized 
in TSLP Tg mice are also modulated in higher-order 
primate species.
Discussion
In this comprehensive study, we utilized TSLP Tg mice, 
which present with the hallmarks of human chronic 
asthma, as a murine model of the disease to study 
the expression and regulation of putative biomarkers. 
Proteome analysis identified over 40 proteins upregu-
lated in the BAL fluid of TSLP Tg mice, and a sub-
set of these was chosen for further examination by 
western blot, ELISAs, or qRT-PCR of lung tissue. 
Subsequently, we investigated which of these bio-
markers are present in mice with developing asthma to 
identify early-onset biomarkers. As murine BAL cells, 
a surrogate for human induced-sputum cells, had not 
previously been examined for their utility in disease 
and treatment biomarker identification, we examined 
the gene expression profiles of BAL cell mRNA for 
biomarker and chemokine/chemokine receptor genes 
indicative of a chronic asthma phenotype. Finally, as 
corticosteroids are a standard, efficacious treatment 
for human asthma, we ascertained which biomarkers 
are reduced during treatment of TSLP Tg mice and 
validated these in a cynomolgus model of asthma.
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Figure 5. Reduction of disease biomarkers in HDMA-challenged NHP following corticosteroid treatment. BAL fluid was collected from HDMA-challenged 
nhP either before (“Pre”) or after (“Post”) 2 weeks of corticosteroid therapy (see Methods). Western blot (“WB”) for AMcase, sIcAM-1, and cLcA1 was 
performed, and band intensities were quantified using a Typhoon scanner (A). Representative western blot results are also shown. BAL fluid GP-39 was 
assayed via eLISA (B). 
notes: each animal is represented by different colored symbol. *P , 0.05; **P , 0.01; ***P , 0.001.
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Previous studies identifying murine biomarkers 
of asthma have mainly relied upon the OVA-induced 
asthma model.6,8–14 While very fruitful in decipher-
ing the mechanisms of asthma, the model has been 
criticized for having a few potential shortcomings. 
The standard or acute model of OVA-induced asthma 
generally administers aerosolized OVA three times in 
a one-week period, which induces the cellular activa-
tion and goblet cell hypertrophy/activation but not the 
extensive tissue remodeling characteristic of human 
asthma.15 Chronic models of OVA-induced asthma 
provoke collagen deposition and extensive tissue 
remodeling but can induce a state of partial tolerance 
rather than increased cellular inflammation.10,15,16 
Thus, we chose to utilize TSLP Tg mice, a different 
model of chronic asthma. These mice constitutively 
express TSLP under a lung-specific promoter,3 and as 
TSLP sits at the top of a cascade that leads to produc-
tion of IL-4, IL-5, and IL-13 and activation of eosino-
phils and Th2 cells,17 TSLP Tg mice present with the 
characteristic properties of asthma (Fig. S1 in the 
Supplemental Information). As TSLP is  constitutively 
expressed in the lung, these mice continue to exhibit 
progressively worse asthma pathology  throughout 
their lives. Additionally, in contrast to previous 
 studies using dexamethasone to prevent the onset of 
inflammation associated with OVA-induced asthma,8,9 
12 week-old TSLP Tg mice have chronic, extensive 
asthma- associated inflammation and pathology pres-
ent for ~3–5 weeks before treatment. As these mice 
express TSLP in the lung constitutively, the underly-
ing cause of the disease continues during treatment. 
Thus, TSLP Tg mice can be considered a better surro-
gate model of human asthma, where therapy is started 
after symptoms and pathology exist, and the causal 
sources of the disease continue during treatment. 
Using this mouse model, we characterized  proteins 
in BAL fluid that could function as biomarkers of 
asthma towards the goal of determining which are 
modulated during treatment.
The majority of proteins identified by mass spec-
trometry of asthmatic BAL fluid were enzymes, and 
several of these and related proteins were selected for 
follow-up by ELISA and qRT-PCR. As several of the 
identified proteins are general indications of inflam-
mation and likely present during other non-allergic 
models of lung inflammation, a panel of biomark-
ers was selected based upon a logical association 
of the biomarkers to asthmatic processes. AMCase 
(gene name Chia), GP-39 (Chi3l1), YM1 (Chi3l3), 
and YM2 (Chi3l4) are all members of the chitinase 
or chitinase-like family and have previously been 
associated with asthma,18–20 although YM1 and YM2 
do not as yet have an identified human orthologue. 
MMP12 (Mmp12) is another enzyme with elastolytic 
activity involved in the local accumulation of cellu-
lar inflammation in the lung.21,22 Mucus production 
and airway remodeling are two key characteristics 
of asthma, so proteins  representing these processes 
were also  chosen as putative biomarkers: FCGBP 
(Fcgbp), although not yet characterized in the lung, 
has a mucin-like structure,23 and CLCA3 (Clca3), the 
murine homologue of human CLCA1, has been impli-
cated in airway goblet cell hyperplasia and mucus pro-
duction.24,25 In addition, RETNLβ (Retnlb) is thought 
to play a role in airway fibrosis,26,27 and KLK1 (Klk1) 
is a serine protease that may be involved in gener-
ating mediators of airway hyperresponsiveness.28,29 
The pIgR (Pigr) was also chosen due to its important 
role in delivering IgA, the major immunoglobulin 
at mucosal surfaces, across the respiratory epithe-
lium.30,31 Several proteins involved in the recognition 
of and defense against microbes were upregulated in 
the BAL fluid of the asthmatic TSLP Tg mice (see 
Table S1 in the Supplemental Information), and a 
subset of these was also chosen for further analysis: 
PGLYRP1 (Pglyrp1), Reg3γ (Reg3g), LTF (Ltf), and 
LCN2 (Lcn2).32–35 Finally, as eosinophils are highly 
involved in the pathophysiology of asthma, a subset 
of eosinophil-associated genes was selected. Inter-
cellular adhesion molecule 1 (ICAM-1; Icam1) is 
expressed on the vascular endothelium and is involved 
in the adhesion of chemotaxing leukocytes, while 
eosinophil cationic protein (ECP; Ear11), eosinophil 
peroxidase (EPX; Epx), and eosinophil major basic 
protein (EMBP; Prg2) are three eosinophil-asso-
ciated activation proteins.36,37 In BAL cell mRNA, 
4 genes were added to the analysis: uteroglobin is an 
anti-inflammatory protein constitutively produced 
by airway epithelial cells, and EGFR is a receptor 
for members of the epithelial growth factor family 
also expressed by the airway epithelium, although 
the secreted form of EGFR is thought to act as an 
antagonist. CTSH is an amino peptidase produced by 
lung macrophages, and ITLN2 is a secreted protein of 
unknown function.
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Some of the selected proteins have been described 
in association with asthma (eg, CLCA3, YM1, YM2, 
AMCase),6,10–14,38 but several had not been character-
ized as being possible asthma biomarkers (eg, Reg3γ, 
KLK1, ITLN2, LTF). We verified these proteins with 
western blot assays and ELISAs, when reagents were 
available, and performed qRT-PCR of lung tissue for 
the entire set of biomarkers, allowing us to exam-
ine mRNA versus protein expression. Interestingly, 
mRNA upregulation did not always mirror results 
obtained at the protein level: ICAM-1, for instance, 
was significantly increased at the protein level but not 
modulated at the mRNA level, while other biomark-
ers, such as LCN2 or GP-39, were highly upregu-
lated at the protein level but only ~2-fold increased 
via qRT-PCR analysis (Fig. 2 and Table 1). As such, 
biomarkers in the “Intermediate” expression cat-
egory, although only upregulated between 1.8- and 
7-fold, should not be overlooked as they could give 
more discernable differences at the protein rather 
than mRNA level.
As TSLP Tg mice begin to develop the hallmarks 
of asthma around 5 weeks of age and progress to a 
state of chronic asthma over the subsequent month, 
we were able to utilize 5 week-old TSLP Tg mice 
to identify biomarkers present in the early stages 
of the disease. Not surprisingly, Clca3, Chi3l4, and 
Ear11, the biomarkers that exhibited the highest-
fold upregulation at the mRNA level in 9 week-old 
TSLP Tg (chronic) asthmatic mice, were also the 
most highly increased during early development of 
asthma. However, the upregulation of the other bio-
markers was not as great in 5 week-old mice, as bio-
markers in the “High” lung category, such as Chi3l3 
(YM1) and Mmp12, fell to the “Intermediate” cat-
egory, and Chia (AMCase), Pglyrp1, Klk1, Lcn2, 
Epx, and Chi3l1 (GP-39) were no longer . 1.8-fold 
increased in 5 week-old TSLP Tg mice (Table 3). 
These differences should be  appreciated when 
designing biomarker panels of chronic versus early 
asthma. Because TSLP Tg mice develop asthma as 
they age, this study was unable to determine if any of 
the above biomarkers are differentially modulated in 
younger versus older mice with similar disease. No 
differences were appreciated in male versus female 
mice, however.
Whereas most studies pertaining to asthma bio-
marker identification and validation have used BAL 
fluid and lung tissue as proximal fluids/tissues,3,8,11,13,14,38 
we thought that the examination of BAL cell mRNA 
from TSLP Tg mice could be particularly fruitful in 
following the expression of asthma biomarkers. As 
continued patient participation in clinical trials or 
therapies is closely associated with the invasiveness of 
the protocol, we reasoned that BAL cells—considered 
a murine surrogate for human induced-sputum cells—
were worth testing for biomarkers because human 
sputum cells are more easily acquired than lung 
biopsies. Being easily acquired, BAL cells could be 
useful not only in disease diagnosis but for determina-
tion of disease stage (such as early versus late or mild 
versus severe), which could aid clinicians in select-
ing the most effective treatment regimens. In addition, 
BAL cell biomarkers could be valuable in monitoring 
efficacy of treatment and making modifications when 
needed.
Interestingly, genes in the “High” lung expression 
category also fell into the same category of BAL cell 
mRNA expression (Tables 1 and 2), suggesting that 
the cellular infiltrate in the lung likely contributes to 
the expression of these biomarkers. As eosinophils 
constitute over 80% of the cells in the BAL of TSLP 
Tg mice, it was not surprising that eosinophil acti-
vation genes Prg2 (EMBP), Epx, and Ear11 were 
very highly increased in BAL cell mRNA. However, 
epithelial-associated genes (such as Clca3 or Retnlb) 
were also in this category, suggesting possible epi-
thelial cell contamination, although Chia, the gene 
coding for AMCase, was not expressed in BAL cell 
mRNA (Table 2), despite that AMCase is highly 
expressed in epithelial cells.39,40 Taken together, our 
results suggest that BAL cell analysis may be useful 
in monitoring disease and treatment biomarkers, and 
that subsets of BAL cells may be a non-traditional 
source of several proteins during asthma.
We also show that BAL cell mRNA can be used to 
generate a “cellular signature” representative of the 
asthmatic airway constituents through examination 
of chemokine and chemokine receptor genes. CCR3 
(CD193) is highly expressed on eosinophils and also 
detectable on Th2 cells, binding chemokines CCL5 
(RANTES), CCL8 (monocyte chemotactic protein-2), 
CCL11 (Eotaxin-1), CCL22 (macrophage-derived 
chemokine), and CCL24 (Eotaxin-2).36,37,41–48 CCR4 
is found on memory Th2 cells and binds CCL22,48–50 
whereas CCR6 is found on eosinophils and memory 
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Th2 cells.36,37 Consistent with their receptor expression, 
CCL5, CCL8, CCL11, and CCL24 are important in 
eosinophil trafficking and activation, whereas CCL22 
functions to recruit Th2 cells to the lung.36,37,41,42,45–51 
In TSLP Tg mice, neutrophils are quite rare and 
generally represent , 3% of the BAL cell subsets. 
 Correspondingly, Cxcr1 and Cxcr2, receptors present 
on neutrophils, were not expressed in BAL cell mRNA. 
Ccr3 and Ccr6, receptors on eosinophils, and Ccr4, 
present on Th2 cells, were enhanced in asthmatic 
mice, however, and dexamethasone treatment reduced 
expression of these receptors. Thus, examination of 
BAL cell mRNA could function to both identify air-
way infiltrates and monitor treatment. Our model of 
chronic asthma is characterized by eosinophilia, but 
the identification of a BAL “cellular signature” can 
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Figure 6. comparisons and summaries of biomarker expression. (A) Comparison of biomarkers upregulated in lung tissue mRNA, in BAL fluid/BAL cell 
mrnA, or in both compartments, of 9-week old TSLP Tg mice. (B) Biomarkers upregulated in lung tissue mrnA of 5-week old TSLP Tg mice. qrT-Pcr 
of BAL cell mrnA was not performed due to low numbers of BAL cells at this time point. (c) comparison of biomarkers with reduced expression in lung 
tissue mrnA and/or BAL cell mrnA following 1 week of steroid treatment in TSLP Tg mice. chi3l3 (YM1), chi3l1 (gP39), and pIgr proteins were also 
reduced in BAL fluid, although not reduced at the mRNA level. (D) Summary of biomarkers of asthma found in lung tissue mRNA, BAL fluid, or BAL cell 
mRNA during chronic asthma; in lung tissue mRNA during developing asthma; and those biomarkers in lung tissue mRNA, BAL fluid, or BAL cell mRNA 
that are reduced with corticosteroid treatment. 
notes: For asthma biomarker categories, large checkmarks indicate a biomarker classified in the “High” expression category (.6-fold increased), small 
checkmarks indicate a biomarker categorized in the “Intermediate” expression category (1.5- to 6-fold increased), and dashes indicate biomarkers not 
upregulated in asthmatic mice. In treatment biomarker categories, a checkmark indicates the biomarker was significantly reduced upon corticosteroid 
treatment; a dash indicates a biomarker not reduced upon treatment.
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also be extended to diagnose neutrophilic lung dis-
eases or changes in the BAL cell constituents during 
the progression or treatment of the disease.
An interesting dichotomy appeared upon compari-
son of lung tissue and BAL cell mRNA expression 
in dexamethasone-treated TSLP Tg mice. Treatment 
reduced signs of asthma, but the most-highly upregu-
lated lung biomarker genes were unmodulated. Taken 
together with the observation that these same genes are 
highly upregulated in 5 week-old TSLP Tg mice dur-
ing the early development of asthma, it is likely that 
Clca3, Chi3l4 (YM2), and Ear11 are the first biomark-
ers to increase during disease and the last biomarkers 
to decline in response to therapy. Therefore, these are 
likely excellent disease biomarkers but poor biomark-
ers of early response to treatment in lung tissue. On 
the other hand, biomarkers such as GP-39, LCN2, 
sICAM-1, and YM1 or Prg2 (EMBP), Epx, and Klk1, 
which are significantly downregulated upon corticos-
teroid treatment in TSLP Tg mouse BAL fluid and 
lung tissue mRNA, respectively, are good indicators of 
early therapeutic intervention. Similarly, most of the 
biomarkers increased in BAL cell mRNA are lessened 
with treatment and could function in a similar capac-
ity. Biomarkers of disease and treatment in the various 
proximal fluids and tissues are summarized in Figure 6. 
Examination of disease and treatment biomarkers in 
HDMA-sensitized and challenged monkeys (Fig. 5A 
and B) support these observations, and ongoing long-
term studies are validating the set of biomarkers in 
proximal fluid and tissues from asthmatic humans. The 
homogeneity of the TSLP Tg mouse strain and sub-
sequent coordinated biomarker expression prevented 
the identification of biomarker panels—groups of bio-
markers that together are a better indicator of disease 
or treatment efficacy, compared to individual mea-
surement—but panel identification and multi-variate 
analyses are being explored in ongoing human studies, 
allowing the fine-tuning of these biomarkers during 
human asthma.
Taken together, the studies presented herein sig-
nificantly advance the field of asthma disease and 
treatment biomarkers by providing a comprehensive 
study of various proximal fluids and tissues in murine 
and cynomolgus models of chronic asthma and reveal 
BAL cells as a fruitful proximal tissue for biomarker 
analysis for diagnosis of disease stage and treatment 
efficacy.
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Figure s1. characterization of TSLP Tg mice as a model of chronic 
asthma. Lung tissue was removed from 9-week old WT or TSLP Tg mice 
and examined for lung pathology by h&e staining (A) or for mucus pro-
duction by PAS staining (B). eosinophils in the BAL were enumerated 
by Wright-giemsa staining of cytospun cells (c). The expression of IL-4, 
IL-5, or IL-13 in WT and TSLP Tg mice was assayed using qrT-Pcr (c) 
or eLISA (D). experiments are representative of at least 5 independent 
experiments.
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